<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04858360</url>
  </required_header>
  <id_info>
    <org_study_id>N-20200073 1st sub-project</org_study_id>
    <nct_id>NCT04858360</nct_id>
  </id_info>
  <brief_title>Inhibition of Non-histaminergic Pruritus Applied Using 3 Different Pruritogens</brief_title>
  <official_title>Evaluation of the Effect of Repeated Administration of Topical Local Anaesthetic Mixture of Lidocaine and Prilocaine (EMLA) in a Model of Non-histaminergic Itch Induced by Cowhage.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aalborg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aalborg University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      With this experiment, we want to use to investigate whether repeated application of EMLA&#xD;
      cream as a tool to modulate non-histaminergic itching, which is produced using small needles&#xD;
      from the plant mucuna pruriens (it is known that antihistamine does not attenuate this form&#xD;
      of itch) and we want to compare the effect of short (1 hour) and prolonged (3 hours)&#xD;
      application of EMLA. The sub-project takes place in 3 sessions over a period of 3 consecutive&#xD;
      days (24 hours apart). All sessions will be identical.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measuring itch intensity by computerized Visual Analog Scale Scoring</measure>
    <time_frame>For 9 minutes</time_frame>
    <description>We will ask the subjects to rate the sensation of itch on a 100 mm VAS scale ranging from 0 to 100 where 0 indicates &quot;no itch&quot; and 100 indicates &quot;worst itch imaginable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measuring pain intensity by computerized Visual Analog Scale Scoring</measure>
    <time_frame>For 9 minutes</time_frame>
    <description>We will ask the subjects to rate the sensation of pain on a 100 mm VAS scale ranging from 0 to 100 where 0 indicates &quot;no pain&quot; and 100 indicates &quot;worst pain imaginable&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Superficial blood perfusion measurement</measure>
    <time_frame>After 1 hour</time_frame>
    <description>Superficial blood perfusion is measured by a Speckle contrast imager</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Superficial blood perfusion measurement</measure>
    <time_frame>After 3 hours</time_frame>
    <description>Superficial blood perfusion is measured by a Speckle contrast imager</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Superficial blood perfusion measurement</measure>
    <time_frame>10 min after cowhage application</time_frame>
    <description>Superficial blood perfusion is measured by a Speckle contrast imager</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measuring Alloknesis</measure>
    <time_frame>After 1 hour</time_frame>
    <description>Alloknesis sensation is measured using a standardized sensory brush exerting a force of 200 to 400 mN.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measuring Alloknesis</measure>
    <time_frame>After 3 hours</time_frame>
    <description>Alloknesis sensation is measured using a standardized sensory brush exerting a force of 200 to 400 mN.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measuring Alloknesis</measure>
    <time_frame>10 min after cowhage application</time_frame>
    <description>Alloknesis sensation is measured using a standardized sensory brush exerting a force of 200 to 400 mN.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measuring Hyperknesis</measure>
    <time_frame>After 1 hour</time_frame>
    <description>Hyperknesis is measured by using mildly pruritic, non-painful von Frey nylon filaments of a predetermined intensity (generally 5-30 miliNewton of force).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measuring Hyperknesis</measure>
    <time_frame>After 3 hours</time_frame>
    <description>Hyperknesis is measured by using mildly pruritic, non-painful von Frey nylon filaments of a predetermined intensity (generally 5-30 miliNewton of force).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measuring Hyperknesis</measure>
    <time_frame>10 min after cowhage application</time_frame>
    <description>Hyperknesis is measured by using mildly pruritic, non-painful von Frey nylon filaments of a predetermined intensity (generally 5-30 miliNewton of force).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measuring Erythema</measure>
    <time_frame>After 1 hour</time_frame>
    <description>The onset of erythema is measured with a spectrometer (ColorMeter, DSM II; Cortex Technology, Hadsund, Denmark).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measuring Erythema</measure>
    <time_frame>After 3 hours</time_frame>
    <description>The onset of erythema is measured with a spectrometer (ColorMeter, DSM II; Cortex Technology, Hadsund, Denmark).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measuring Erythema</measure>
    <time_frame>10 min after cowhage application</time_frame>
    <description>The onset of erythema is measured with a spectrometer (ColorMeter, DSM II; Cortex Technology, Hadsund, Denmark).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measuring Skin Pigmentation</measure>
    <time_frame>After 1 hour</time_frame>
    <description>The onset of skin pigmentation is measured with a spectrometer (ColorMeter, DSM II; Cortex Technology, Hadsund, Denmark).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measuring Skin Pigmentation</measure>
    <time_frame>After 3 hours</time_frame>
    <description>The onset of skin pigmentation is measured with a spectrometer (ColorMeter, DSM II; Cortex Technology, Hadsund, Denmark).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measuring Skin Pigmentation</measure>
    <time_frame>10 min after cowhage application</time_frame>
    <description>The onset of skin pigmentation is measured with a spectrometer (ColorMeter, DSM II; Cortex Technology, Hadsund, Denmark).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Itch</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emla 1 hour</intervention_name>
    <description>At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then one area will be pre-treated with cutaneous 2.5% lidocaine/2.5% prilocaine cream (EMLA cream) for 1 hour.</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EMLA 3 hours</intervention_name>
    <description>At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then one area will be pre-treated with cutaneous 2.5% lidocaine/2.5% prilocaine cream (EMLA cream) for 3 hours.</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle cream for 1 hour</intervention_name>
    <description>At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then two area will be pre-treated with a vehicle cream for 1 h.</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle cream for 3 hours</intervention_name>
    <description>At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then two area will be pre-treated with a vehicle cream for 3 h.</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cowhage</intervention_name>
    <description>Cowhage spicules are 1-2 mm in length and have a diameter of 1-3 Î¼m. The spicules are inserted by gently rubbing 30-35 spicules into a 1 cm diameter skin area.</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy men and women&#xD;
&#xD;
          -  18-60 years&#xD;
&#xD;
          -  Speak and understand English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Drug addiction defined as any use of cannabis, opioids or other drugs&#xD;
&#xD;
          -  Previous or current neurologic, musculoskeletal or mental illnesses that may affect&#xD;
             the results (e.g. neuropathy, muscular pain in the upper extremities, etc.).&#xD;
&#xD;
          -  Lack of ability to cooperate&#xD;
&#xD;
          -  Current use of medications that may affect the trial such as antihistamine medications&#xD;
             or pain killers.&#xD;
&#xD;
          -  Skin diseases&#xD;
&#xD;
          -  Hypersensitivity to papaya and mango fruit, cashew nuts and rubber latex&#xD;
&#xD;
          -  Consumption of alcohol or painkillers 24 hours before the study days and between these&#xD;
&#xD;
          -  Acute or chronic pain&#xD;
&#xD;
          -  Participation in other trials within 1 week of study entry (4 weeks in the case of&#xD;
             pharmaceutical trials)&#xD;
&#xD;
          -  Known history of anaphylactic shock, or local allergy (contact dermatitis) to&#xD;
             lidocaine, prilocaine or other local anaesthetics of the amide type.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silvia lo Vecchio</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aalborg University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Silvia Lo Vecchio</last_name>
    <phone>21397785</phone>
    <email>slv@hst.aau.dk</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 21, 2021</study_first_submitted>
  <study_first_submitted_qc>April 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aalborg University</investigator_affiliation>
    <investigator_full_name>Silvia Lo Vecchio</investigator_full_name>
    <investigator_title>PhD, Assistant Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine, Prilocaine Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

